Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri

Sanfilippo, Joseph S.; Miseljic, Slobodan; Yang, Ai-Ru; Doering, David L.; Shaheen, MennatAllah; Wittliff, James L.

doi:10.1002/(sici)1097-0142(19960215)77:4<710::aid-cncr17>3.0.co;2-3

Cited by 14 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies were performed on relatively small series, because only one group included more than 100 cases (Lšsch et al, 1996). In one study, Cat D levels were quantified by ELISA (Maudelonde et al, 1990), and in three (Nazeer et al, 1992;Scambia et al, 1995;Sanfilippo et al, 1996) by an immunoradiometric (IRMA) procedure similar to that used by us. In another article, Cat D was detected by immunohistochemistry (IHC) (Lšsch et al, 1996).…”

Section: Discussionsupporting

confidence: 84%

“…Our data in endometrial cancer are similar to those published by Sanfilippo et al (1996) and higher than those reported by three other groups (Maudelonde et al, 1990;Nazeer et al, 1992;Scambia et al, 1995). The reasons underlying these divergent results are not clear because most of these authors used essentially the same methodology as that used by us.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer

et al. 1999

View full text Add to dashboard Cite

Total cytosolic cathepsin D (Cat D) levels were estimated by an immunoradiometric assay in a series of 156 consecutive patients with surgical stages I–III primary endometrial adenocarcinoma. Simultaneously, the tissue content of both oestrogen (ER) and progesterone (PR) receptors, and p185 HER-2/neu , DNA content (ploidy), and the fraction of S-phase cells (S-phase) were also estimated. Tumoral Cat D content ranged from 0 to 243 pmol mg −1 protein (median 44 pmol mg −1 protein) and was not associated with any of the established clinicopathological and biological prognostic variables, with the exception of a weak positive correlation with the tumoral p185 HER-2/neu levels. Univariable analysis performed on a subset of 97 patients, followed for a minimum of 2 years or until death, showed that patient age at diagnosis, high histological grade, advanced surgical stage, vascular invasion, positive peritoneal cytology, low levels of Cat D, negative ER and PR status, aneuploidy, and high S-phase were predictive of the presence of persistent or recurrent disease. However, multivariable analysis revealed that only histological grade, surgical stage, Cat D and PR were significantly associated with the patient's outcome. From these findings, we conclude that Cat D is an independent prognostic factor in endometrial adenocarcinoma, its low levels being associated with a worse clinical outcome. © 1999 Cancer Research Campaign

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Specific binding capacities of ER , PR , and epidermal growth factor receptor (EGFR) , and the level of human epidermal growth factor receptor‐2 (HER‐2/neu) oncoprotein were determined as described earlier. ER and PR measurements were performed by enzyme immunoassay (EIA) and/or ligand‐binding methods using standardized reagents in the presence of a reference specimen .…”

Section: Methodsmentioning

confidence: 99%

Expression of Urokinase‐Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI‐1) in Human Breast Carcinomas and Their Clinical Relevance

Andres¹,

Edwards²,

Wittliff³

2012

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Serine proteases convert plasminogen to plasmin which is involved in tissue remodeling under physiologic and pathophysiologic conditions, including breast carcinoma invasion and progression. Both urokinase-type plasminogen activator (uPA) and pro-uPA associate with uPA receptor (uPAR) on target cells, where plasminogen activator inhibitors (e.g., PAI-1) may modulate their activities. Expression levels of these factors were compared in breast carcinomas relative to patient characteristics, carcinoma features, and clinical outcome. uPA, uPAR, and PAI-1 were quantified by enzyme-linked immunosorbent assay (ELISA) in extracts of 226 biopsies while estrogen receptor (ER) and progestin receptor (PR) were determined by enzyme immunoassay (EIA) or radio-ligand binding. Each set of assays contained a novel reference specimen with known quantities of each of these five analytes. Levels in ng/mg protein of these biomarkers exhibited ranges: uPA (0-12.3); uPAR (0-19.5); PAI-1 (0-91.2). When considered independently, expression of uPA, uPAR, or PAI-1 was unrelated to patient age or menopausal status. Although no correlation was observed between each analyte with stage, grade, or ER/PR status, levels appeared to differ with pathology and nodal status. A dendrogram from hierarchical clustering of uPA, uPAR, and PAI-1 levels in 106 specimens revealed three clusters of breast cancer patients. Kaplan-Meier analyses of uPA, uPAR, and PAI-1 indicated a correlation with overall survival (OS), suggesting collective examination of these biomarkers is useful in predicting clinical outcome of breast cancer.

show abstract

“…The concentration and distribution of cytosolic and nuclear receptors (ER, PgR) under steroid stimulation prove the extreme sensitivity to development fibrocystic change from exogenous steroids. Testosterone and its metabolites might be able to induce the secretion of mitogenic factors and stimulate the production of proteins such as cathepsin D and plasminogen activator, which may degrade the extracellular matrix and thereby accelerate the growth factors [18]. ER is an intracellular protein, but its exact localization is very controversial.…”

Section: Discussionmentioning

confidence: 99%

Hyperplastic Changes and Receptor Status in the Breast Tissue of Bodybuilders Under Anabolic?androgenic Steroid Stimulation

Salazar

Torres²,

Avila³

et al. 2000

Archives of Andrology

View full text Add to dashboard Cite

Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri

Abstract: Determination of the frequency and levels of EGF receptors, HER-2/neu protein, and cathepsin D in uteri with and without cancer and the availability of reference materials developed in our laboratory, will allow evaluation of their prognostic value in cancers of the uterus.

Cited by 14 publications

References 27 publications

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer

Expression of Urokinase‐Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI‐1) in Human Breast Carcinomas and Their Clinical Relevance

Hyperplastic Changes and Receptor Status in the Breast Tissue of Bodybuilders Under Anabolic?androgenic Steroid Stimulation

Contact Info

Product

Resources

About